Corcept's new drug, relacorilant, shows promise with positive Phase 3 results and an FDA decision expected. Learn more about ...

A bipartisan Senate bill dubbed the “Skinny Label, Big Savings Act” was introduced in January. The bill would expand the scope of protection ...

Teva Pharmaceuticals filed a patent infringement lawsuit against Amneal Pharmaceuticals alleging that their generic version ...

Generic drugmakers could be significantly impacted by President Trump's decision to double the tariff on Chinese goods to 20% ...

The shoe brand has launched "For Playground Earth," a new anthem and collection created to "push people to play outside." ...

The drugs are listed in alphabetical order. Aprepitant oral suspension: Merck reported a shortage of Emend, its aprepitant oral suspension. Merck did not provide a reason for the shortage. The ...

Federal Circuit says only patents claiming the active ingredient of a drug are eligible for listing | Injunction against Teva ...

Weeks after settling a five-year patent dispute with the U.S. | Gilead set aside approximately $200 million for a potential ...

NEW YORK CITY, NY / ACCESS Newswire / March 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Teva Pharmaceutical Industries Ltd. failed to convince the Federal Circuit to reconsider a December ruling that five patents ...

The FDA had approved Otulfi in September 2024 to treat Crohn’s disease, ulcerative colitis, psoriasis and active psoriatic arthritis. Information on pricing is not yet available.

Across six asthma biologics, adherence differed by the therapy given and was often low or irregular based on three adherence measures, according to a presentation here.This cross-sectional cohort ...